-
Merck Injects $1 Billion To Expand Vaccine Production In US
Tuesday, March 11, 2025 - 11:26am | 520Read More...On Tuesday, Merck & Co Inc (NYSE:MRK) opened a new $1 billion, 225,000-square-foot facility for vaccine manufacturing at its Durham, North Carolina, site. This expansion is a crucial component of the more than $12 billion Merck has invested in the U.S. since 2018. It’s focused on...
-
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Tuesday, September 10, 2024 - 2:09pm | 497Read More...The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) to resolve claims against the company for its role in the city’s opioid epidemic. Under the agreement, Teva will pay an initial $35 million by the end...
-
Argus Concerned With Near-Term Challenges At AstraZeneca
Tuesday, July 12, 2016 - 9:37am | 279Read More...AstraZeneca plc (ADR) (NYSE: AZN) shares are currently trading at a discount to the S&P 500 Pharma companies, which Argus’ Stephen Biggar views as warranted, given the earnings challenges being faced by the company due to its current business transition. Biggar initiated coverage of the...
-
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Wednesday, February 25, 2015 - 12:31pm | 177Read More...In a report published Wednesday, CRT Capital analyst Tim Chiang increased his price target on Buy-rated shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to $220 from a previous $180 following Tuesday's conference call, which highlighted strong fundamentals and the strategic rationale...
